Drug Profile
Pavinetant - Tempest Therapeutics
Alternative Names: AZ 12472520; AZD 2624; AZD 4901; MLE-4901Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Developer AstraZeneca; Tempest Therapeutics
- Class Small molecules
- Mechanism of Action Hormone modulators; Neurokinin 3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Hot flashes; Polycystic ovary syndrome; Schizophrenia
Most Recent Events
- 08 Nov 2017 Discontinued - Phase-II for Hot flashes in United Kingdom (PO)
- 08 Nov 2017 Discontinued - Phase-II for Polycystic ovary syndrome in USA, Germany, United Kingdom (PO)
- 08 Nov 2017 Millendo Therapeutics terminates a phase II trial in Hot flashes in United Kingdom after assessment of the clinical risks and benefits of the program (PO) (NCT02668185)